Tema Etfs LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 14,239 shares of the life sciences company's stock, valued at approximately $1,903,000.
A number of other hedge funds also recently modified their holdings of ILMN. Capital World Investors increased its position in Illumina by 408.6% in the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after buying an additional 14,481,232 shares during the last quarter. WCM Investment Management LLC grew its stake in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after acquiring an additional 867,673 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after acquiring an additional 27,618 shares during the period. Brown Advisory Inc. increased its holdings in Illumina by 54,220.9% in the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after acquiring an additional 1,909,118 shares during the last quarter. Finally, Norges Bank bought a new stake in Illumina in the 4th quarter valued at about $228,714,000. Institutional investors own 89.42% of the company's stock.
Illumina Stock Performance
Shares of ILMN stock traded down $4.84 on Wednesday, reaching $79.37. The stock had a trading volume of 2,722,202 shares, compared to its average volume of 2,320,823. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock has a market cap of $12.56 billion, a P/E ratio of -10.33, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The company has a 50 day simple moving average of $78.46 and a 200 day simple moving average of $110.24.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same period last year, the firm posted $0.98 earnings per share. The business's revenue for the quarter was down 1.4% on a year-over-year basis. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.
Insiders Place Their Bets
In related news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the purchase, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 2.60% of the company's stock.
Analyst Ratings Changes
Several research firms have issued reports on ILMN. Stephens restated an "overweight" rating and set a $105.00 target price on shares of Illumina in a research report on Tuesday. Barclays decreased their price objective on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a report on Thursday, April 10th. JPMorgan Chase & Co. reduced their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and cut their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Illumina currently has a consensus rating of "Moderate Buy" and an average price target of $128.15.
Check Out Our Latest Report on ILMN
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
